Genmab A (GMAB) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $7.0 billion.
- Genmab A's Total Liabilities rose 45019.58% to $7.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 billion, marking a year-over-year increase of 45019.58%. This contributed to the annual value of $7.0 billion for FY2025, which is 45019.58% up from last year.
- As of Q4 2025, Genmab A's Total Liabilities stood at $7.0 billion, which was up 45019.58% from $1.3 billion recorded in Q3 2025.
- Genmab A's Total Liabilities' 5-year high stood at $7.0 billion during Q4 2025, with a 5-year trough of -$10.0 million in Q1 2024.
- In the last 3 years, Genmab A's Total Liabilities had a median value of $1.3 billion in 2024 and averaged $3.3 billion.
- The largest annual percentage gain for Genmab A's Total Liabilities in the last 5 years was 6586000.0% (2025), contrasted with its biggest fall of 7900.25% (2025).
- Genmab A's Total Liabilities (Quarter) stood at $545.0 million in 2023, then soared by 134.31% to $1.3 billion in 2024, then skyrocketed by 450.2% to $7.0 billion in 2025.
- Its Total Liabilities stands at $7.0 billion for Q4 2025, versus $1.3 billion for Q3 2025 and $1.2 billion for Q2 2025.